The Influence of Topical Prostaglandin Analogues in Inflammation After Selective Laser Trabeculoplasty Treatment

Ayala, Marcelo; Chen, Enping

doi:10.1089/jop.2011.0084

Cited by 18 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the follow up for the current study is short, a previous study showed that intraocular pressure remains stable at six months; therefore, one month values may be predictive of future intraocular pressure control. (9,17,19) The authors suggest that the results of the current study be confirmed with a larger multicenter randomized prospective trial that includes different glaucoma subtypes, a longer follow up period, and a more diverse patient population.…”

Section: Resultssupporting

confidence: 56%

A (randomized/prospective/pilot) study comparing the efficacy of Selective Laser Trabeculoplasty versus brimonidine tartrate 0.2%/timolol maleate 0.5% (Combigan, Allergan inc. Irvine, CA/USA) in lowering intraocular pressure as adjunct therapy in Primary Open Angle Glaucoma.

McWherter

Lanham

Peplinski

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose: To compare the intraocular pressure lowering efficacy of selective laser trabeculoplasty to brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT, Combigan, Allergan inc. Irvine, CA/USA) in patients with uncontrolled primary open-angle glaucoma on a prostaglandin analog alone. A secondary outcome was to evaluate the complication rates of selective laser trabeculoplasty. Patients and Methods: Twenty-three patients were randomized to two treatment groups within this prospective, observer-masked single site, all optometrist, pilot study. Group 1 (N=12) received 360 degrees of selective laser trabeculoplasty as additional treatment while Group 2 (N=11) was started on FCBT. Outcomes of both groups were measured at eight weeks. Results: Both treatment regimens were found to be statistically significant in lowering IOP when used as adjunct therapy. The average IOP reduction for Group 1 and Group 2 was 28.43% (SD = .17) and 28.22% (SD = .12) respectively. The incidence of an intraocular pressure spike following SLT in this patient population was found to be 8.3%. No major complications were observed in this study. Conclusion: Selective laser trabeculoplasty and brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT, Combigan, Allergan inc. Irvine, CA/USA) were shown to be equivalent in lowering intraocular pressure in uncontrolled primary open angle glaucoma patients when used as adjunct therapy for patients on a prostaglandin analog. Additionally, this is the first prospective study of optometrists performing selective laser trabeculoplasty. Although this study had a small sample size, the results appeared to show that efficacy and complication rates were comparable to previously published data; however, these results need to be confirmed with a larger multi-centered trial.

show abstract

Section: Resultssupporting

confidence: 56%

A (randomized/prospective/pilot) study comparing the efficacy of Selective Laser Trabeculoplasty versus brimonidine tartrate 0.2%/timolol maleate 0.5% (Combigan, Allergan inc. Irvine, CA/USA) in lowering intraocular pressure as adjunct therapy in Primary Open Angle Glaucoma.

McWherter

Lanham

Peplinski

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Although the follow up for the current study is short, a previous study showed that intraocular pressure remains stable at six months; therefore, one month values may be predictive of future intraocular pressure control. 11,19,21 The authors suggest that the results of the current study be confirmed with a larger multicenter randomized prospective trial that includes different glaucoma subtypes, a longer follow up period, and a more diverse patient population.…”

Section: Discussionsupporting

confidence: 56%

“…Their study reported that patients receiving SLT as adjunct treatment to a PGA lowered IOP by 6.3 mm Hg (26.07%) while patients who were using a nonprostaglandin agent (Carbonic Anhydrase Inhibitor, Alpha-2 Agonist or Beta Blockers) had a similar 5.77 mm Hg (24.53%) reduction with SLT. 19 There was no statistically significant difference in IOP reduction between either group when SLT was added to patients using a PGA or non-prostaglandin agent. The current study showed a similar IOP percentage reduction to Ayala and Chen, despite difference in treatment protocol.…”

Section: Discussionmentioning

confidence: 78%

Selective Laser Trabeculoplasty Versus Brimonidine Tartrate 0.2%/Timolol Maleate 0.5% As Adjunct Therapy in Primary Open Angle Glaucoma: A Randomized Prospective Trial

McWherter

Lanham²,

Peplinski

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: To compare the intraocular pressure lowering efficacy of selective laser trabeculoplasty to brimonidine tartrate 0.2%/timolol maleate 0.5% in patients with uncontrolled primary open-angle glaucoma on a prostaglandin analog alone. A secondary outcome was to evaluate the complication rates of selective laser trabeculoplasty.Patients and Methods: Twenty-three patients were randomized to two treatment groups within this prospective, observer-masked single site, all optometrist, pilot study. Group 1 (N=12) received 360 degrees of selective laser trabeculoplasty as additional treatment while Group 2 (N=11) was started on FCBT. Outcomes of both groups were measured at eight weeks.Results: Both treatment regimens were found to be statistically significant in lowering IOP when used as adjunct therapy. The average IOP reduction for Group 1 and Group 2 was 28.4% (SD = .17) and 28.2% (SD = .12) respectively. The incidence of an intraocular pressure spike following SLT in this patient population was found to be 8.3%. No major complications were observed in this study.Conclusion: Selective laser trabeculoplasty and brimonidine tartrate 0.2%/timolol maleate 0.5% were shown to be equivalent in lowering intraocular pressure in uncontrolled primary open angle glaucoma patients when used as adjunct therapy for patients on a prostaglandin analog. Additionally, this is the first prospective study of optometrists performing selective laser trabeculoplasty. Although this study had a small sample size, the results appeared to show that efficacy and complication rates were comparable to previously published data; however, these results need to be confirmed with a larger multi-centered trial.Trial Registration: ISRCTN Study ID ISRCTN30070325, retrospectively registered 12/14/2018. http://www.isrctn.com/ISRCTN30070325.

show abstract

“…Spekulationen, nach denen topische Prostaglandine aufgrund ihrer pharmakologischen Verwandtschaft zu SLT-induzierten entzündlichen Prozessen die Effektivität der SLT beeinflussen können, haben sich nicht bestätigt. Die SLT ist bei bereits bestehender Lokaltherapie mit Prostaglandinanaloga nicht mit einem höheren Risiko einer Entzündungsreaktion oder einer verminderten Wirksamkeit assoziiert [24]. Bislang ließ sich auch kein eindeutiger Zusammenhang zwischen Wirksamkeit einer SLT und anderen Glaukomtherapeutika herstellen [25].…”

Section: Indikationen (Glaukomform Glaukomstadium)unclassified

Stellenwert der selektiven Lasertrabekuloplastik (SLT)

Schlote¹

2017

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

Worldwide, in recent years, selective laser trabeculoplasty (SLT) has developed into a very successful therapy for glaucoma. The article provides a review of the literature from PubMed and clinical experience. SLT is equally efficacious to argon laser trabeculoplasty (ALT) and to a first-line glaucoma medication. SLT can be used in most common forms of open-angle glaucoma and ocular hypertension. In contrast to ALT, SLT is repeatable and requires much less energy. SLT has been reported to be also successful in some rare forms of ocular hypertension/glaucoma. There is no negative influence of SLT to other forms of glaucoma treatment. Complications are rare and include intraocular pressure spikes, corneal scarring or corneal decompensation due to endothelial cell damage and cystoid macular edema. The potential of SLT as a first-line treatment of glaucoma is now under investigation. SLT is a low-risk procedure to treat glaucoma in a broad range of indications. Advantages of SLT include the potential to use SLT more and more as a primary treatment procedure. Therefore, SLT is now under intensive investigation worldwide.

show abstract

The Influence of Topical Prostaglandin Analogues in Inflammation After Selective Laser Trabeculoplasty Treatment

Cited by 18 publications

References 24 publications

A (randomized/prospective/pilot) study comparing the efficacy of Selective Laser Trabeculoplasty versus brimonidine tartrate 0.2%/timolol maleate 0.5% (Combigan, Allergan inc. Irvine, CA/USA) in lowering intraocular pressure as adjunct therapy in Primary Open Angle Glaucoma.

A (randomized/prospective/pilot) study comparing the efficacy of Selective Laser Trabeculoplasty versus brimonidine tartrate 0.2%/timolol maleate 0.5% (Combigan, Allergan inc. Irvine, CA/USA) in lowering intraocular pressure as adjunct therapy in Primary Open Angle Glaucoma.

Selective Laser Trabeculoplasty Versus Brimonidine Tartrate 0.2%/Timolol Maleate 0.5% As Adjunct Therapy in Primary Open Angle Glaucoma: A Randomized Prospective Trial

Stellenwert der selektiven Lasertrabekuloplastik (SLT)

Contact Info

Product

Resources

About